Clinical Trial Update: Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49 [Phase 3]

View source ↗

Summary

Phase 3 update evaluating safety and immunogenicity of a single-dose MenACYW meningococcal conjugate vaccine booster in older adults who completed primary vacci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infection

Drugs mentioned

• MenACYW Conjugate Vaccine (MenACWY conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Infection (Healthy Volunteers) | Phase 3 | Status: COMPLETED | Results posted: 2021-04-26